| Item | Details | Source (PMID/DOI/URL if available) | Year |
|---|---|---|---|
| GTN histologic subtypes | Gestational trophoblastic neoplasia (GTN) comprises **invasive mole, choriocarcinoma, placental site trophoblastic tumour (PSTT), and epithelioid trophoblastic tumour (ETT)**. (pqac-00000004, pqac-00000002) | Lin J-K, Jiang F, Xiang Y. *eClinicalMedicine* 77:102890. DOI: 10.1016/j.eclinm.2024.102890; https://doi.org/10.1016/j.eclinm.2024.102890. Senat H et al. DOI: 10.12775/jehs.2024.59.005; https://doi.org/10.12775/jehs.2024.59.005 | 2024 |
| Post-molar diagnostic hCG criterion: plateau | Post-molar GTN can be diagnosed when **hCG remains within ±10% across 4 determinations over 3 weeks** after evacuation. (pqac-00000000, pqac-00000018) | Senat H et al. DOI: 10.12775/jehs.2024.59.005; https://doi.org/10.12775/jehs.2024.59.005 | 2024 |
| Post-molar diagnostic hCG criterion: rise | Post-molar GTN can be diagnosed when **hCG rises by >10% in 3 determinations over 2 weeks**. (pqac-00000000, pqac-00000021) | Senat H et al. DOI: 10.12775/jehs.2024.59.005; https://doi.org/10.12775/jehs.2024.59.005 | 2024 |
| Post-molar diagnostic hCG criterion: persistent detectability | Post-molar GTN can be diagnosed when **hCG remains detectable for >6 months after molar evacuation**. (pqac-00000000, pqac-00000023) | Senat H et al. DOI: 10.12775/jehs.2024.59.005; https://doi.org/10.12775/jehs.2024.59.005. Tempfer C et al. DOI: 10.1055/a-1904-6461; https://doi.org/10.1055/a-1904-6461 | 2024, 2023 |
| Additional GTN diagnostic basis | GTN diagnosis may also be established by **presence of metastases** or **histologic diagnosis** (e.g., invasive mole, choriocarcinoma, PSTT, ETT). (pqac-00000001, pqac-00000000) | Senat H et al. DOI: 10.12775/jehs.2024.59.005; https://doi.org/10.12775/jehs.2024.59.005 | 2024 |
| FIGO anatomical stage I | **Stage I:** disease confined to the uterus. (pqac-00000021) | Senat H et al. DOI: 10.12775/jehs.2024.59.005; https://doi.org/10.12775/jehs.2024.59.005 | 2024 |
| FIGO anatomical stage II | **Stage II:** GTN extends outside the uterus but is limited to genital structures. (pqac-00000001, pqac-00000021) | Senat H et al. DOI: 10.12775/jehs.2024.59.005; https://doi.org/10.12775/jehs.2024.59.005 | 2024 |
| FIGO anatomical stage III | **Stage III:** GTN extends to the lungs, with or without genital tract involvement. (pqac-00000001, pqac-00000021) | Senat H et al. DOI: 10.12775/jehs.2024.59.005; https://doi.org/10.12775/jehs.2024.59.005 | 2024 |
| FIGO anatomical stage IV | **Stage IV:** all other distant metastases. (pqac-00000001, pqac-00000021) | Senat H et al. DOI: 10.12775/jehs.2024.59.005; https://doi.org/10.12775/jehs.2024.59.005 | 2024 |
| WHO/FIGO prognostic score: low risk | **Score 0–6 = low-risk GTN**; typically treated with single-agent chemotherapy. (pqac-00000004, pqac-00000001) | Lin J-K, Jiang F, Xiang Y. DOI: 10.1016/j.eclinm.2024.102890; https://doi.org/10.1016/j.eclinm.2024.102890. Senat H et al. DOI: 10.12775/jehs.2024.59.005; https://doi.org/10.12775/jehs.2024.59.005 | 2024 |
| WHO/FIGO prognostic score: high risk | **Score ≥7 = high-risk GTN**; typically requires multi-agent chemotherapy. (pqac-00000004, pqac-00000001) | Lin J-K, Jiang F, Xiang Y. DOI: 10.1016/j.eclinm.2024.102890; https://doi.org/10.1016/j.eclinm.2024.102890. Senat H et al. DOI: 10.12775/jehs.2024.59.005; https://doi.org/10.12775/jehs.2024.59.005 | 2024 |
| WHO/FIGO prognostic score: ultra-high risk | **Ultra-high-risk** category recognized in later FIGO updates as **score ≥13** or extensive metastasis. (pqac-00000004) | Lin J-K, Jiang F, Xiang Y. *eClinicalMedicine* 77:102890. DOI: 10.1016/j.eclinm.2024.102890; https://doi.org/10.1016/j.eclinm.2024.102890 | 2024 |
| WHO/FIGO score applicability caveat | The standard FIGO/WHO prognostic scoring system is **not applicable to PSTT and ETT**. (pqac-00000004) | Lin J-K, Jiang F, Xiang Y. *eClinicalMedicine* 77:102890. DOI: 10.1016/j.eclinm.2024.102890; https://doi.org/10.1016/j.eclinm.2024.102890 | 2024 |
| Core prognostic score variables | FIGO/WHO scoring incorporates factors such as **antecedent pregnancy, interval since index pregnancy, pretreatment hCG, tumour size, site/number of metastases, and prior failed chemotherapy**. (pqac-00000004, pqac-00000005) | Lin J-K, Jiang F, Xiang Y. DOI: 10.1016/j.eclinm.2024.102890; https://doi.org/10.1016/j.eclinm.2024.102890. Tempfer C et al. DOI: 10.1055/a-1904-6461; https://doi.org/10.1055/a-1904-6461 | 2024, 2023 |


*Table: This table summarizes the core clinical classification framework for gestational trophoblastic neoplasia, including diagnostic hCG criteria, FIGO staging, and WHO/FIGO prognostic score cutoffs. It is useful as a compact reference for disease definition, diagnosis, and risk stratification.*